The efficacy and safety of vemurafenib in therapy of patients with unresectable cutaneous melanoma in the light of updated results of BRIM-3 trial

Abstract

Vemurafenib, inhibitor of the BRAF serine-threonine kinase, is a molecularly targeted drug approved for the treatment of advanced melanoma harboring activating BRAF mutation. Inhibition of the BRAF kinase by vemurafenib leads to reduced signaling through the mitogen-activated protein kinase pathway that plays important role in tumor progression. The BRIM-3 phase III trial evaluating the effectiveness of vemurafenib in patients with metastatic melanoma with BRAF mutations showed significant improvement in progression free survival and overall survival. This review presents extended follow-up results of BRIM-3 trial.